Table 1.

Summary of IL-6/JAK/STAT3 inhibitors in COVID-19.

JAK inhibitor	Function
Baricitinib	JAK 1/2 inhibitor that has been shown to reduce inflammation and a treatment candidate for COVID-19 due to its potential anti-inflammatory and anti-viral effects.
Pacritinib	Oral activator (JAK2) and reduce the progression of acute respiratory distress syndrome and mechanical ventilation in hospitalized patients with COVID-19.
Ruxolitinib	Oral inhibitor of JAK and stops the IL-6 / JAK / STAT3 pathway that can significantly reduce IL-6 levels like upadacitinib and it can be a good treatment option for COVID-19.
Tofacitinib	Inhibits JAK3, JAK1, JAK2, and to a lesser extent TYK2 and inhibits receptor signaling through pairs of JAK2 and because it can suppress the production of different cytokines, such as IL-2, IL-7 and IL-6 can used for patients with COVID-19.
Nezulcitinib	Lung-selective inhibitor of the Janus kinases (JAKs), with potential anti-inflammatory and immunomodulatory activities, is a treatment for acute lung injury associated with COVID-19.
Upadacitinib	Targeting the JAK1 enzyme and decreases the activity of the immune system, reduce the expression of T-helper 2 and 22 cytokines and also the levels of interleukin6 (IL-6) like ruxolitinib that inhibits damage lung in patients with COVID-19.